These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 20155724

  • 1. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 2. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 3. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
    Lang UE, Heger J, Willbring M, Domula M, Matschke K, Tugtekin SM.
    Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
    [Abstract] [Full Text] [Related]

  • 4. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 6. mTOR inhibition: the learning curve in kidney transplantation.
    Weir MR, Diekmann F, Flechner SM, Lebranchu Y, Mandelbrot DA, Oberbauer R, Kahan BD.
    Transpl Int; 2010 May 01; 23(5):447-60. PubMed ID: 20136784
    [Abstract] [Full Text] [Related]

  • 7. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May 01; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 8. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM.
    Transplant Proc; 2010 Nov 01; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [Abstract] [Full Text] [Related]

  • 9. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA.
    Transplant Proc; 2010 Mar 01; 42(2):641-3. PubMed ID: 20304212
    [Abstract] [Full Text] [Related]

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 11. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 12. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B.
    Transpl Int; 2004 Jul 27; 17(6):279-85. PubMed ID: 15221123
    [Abstract] [Full Text] [Related]

  • 13. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H.
    J Heart Lung Transplant; 2007 Jun 27; 26(6):557-64. PubMed ID: 17543777
    [Abstract] [Full Text] [Related]

  • 14. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I, Chan L.
    Transplant Proc; 2011 Mar 27; 43(2):472-7. PubMed ID: 21440737
    [Abstract] [Full Text] [Related]

  • 15. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T, Argudo A, Peña-Cala MC.
    Transplant Proc; 2011 Mar 27; 43(6):2216-9. PubMed ID: 21839237
    [Abstract] [Full Text] [Related]

  • 16. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 17. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
    Campistol JM, Schena FP.
    Nephrol Dial Transplant; 2007 May 15; 22 Suppl 1():i17-22. PubMed ID: 17456614
    [Abstract] [Full Text] [Related]

  • 18. Can mTOR inhibitors reduce the risk of late kidney allograft failure?
    Ponticelli C.
    Transpl Int; 2008 Jan 15; 21(1):2-10. PubMed ID: 17635837
    [Abstract] [Full Text] [Related]

  • 19. The role of mTOR inhibitors in the management of posttransplant malignancy.
    Monaco AP.
    Transplantation; 2009 Jan 27; 87(2):157-63. PubMed ID: 19155967
    [Abstract] [Full Text] [Related]

  • 20. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M.
    Nefrologia; 2011 Jan 27; 31(1):27-34. PubMed ID: 21270910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.